What is Peptone?
Peptone has developed the protein engineering operating system (PeOS), a sophisticated platform designed to automate the search for novel protein variants with enhanced therapeutic properties and improved manufacturability. The company's protein drug discovery engine is instrumental in advancing a range of pre-clinical and late-stage protein therapeutics programs, positioning Peptone at the forefront of biopharmaceutical innovation.
How much funding has Peptone raised?
Peptone has raised a total of $40M across 1 funding round:
Series A
$40M
Series A (2022): $40M with participation from Bessemer Venture Partners, Walden Catalyst Ventures, dRx Capital, and Hoxton Ventures
Key Investors in Peptone
Bessemer Venture Partners
Bessemer Venture Partners is a venture capital firm established in 1911, known for its extensive history and global presence in supporting technology startups.
dRx Capital
dRx Capital is a joint venture investment company focused on catalyzing early-stage digital medicine companies, leveraging networks in pharma, mobile/IT, and venture investment.
Hoxton Ventures
Hoxton Ventures is an early-stage venture capital firm investing in European technology startups with the potential for global scale, having previously backed notable companies like Babylon Health and Darktrace.
What's next for Peptone?
The substantial enterprise-level capital infusion, particularly the recent strategic investment, suggests Peptone is poised for significant scaling and further development of its PeOS platform. This backing will likely accelerate its efforts in drug discovery and therapeutic development, potentially leading to new partnerships and expanded clinical trials. The company's focus on automated protein variant search indicates a strategic move towards optimizing the efficiency and cost-effectiveness of biopharmaceutical production.
See full Peptone company page
